Masoprocol

Identification

Generic Name
Masoprocol
DrugBank Accession Number
DB00179
Background

A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 302.3649
Monoisotopic: 302.151809192
Chemical Formula
C18H22O4
Synonyms
  • erythro-nordihydroguaiaretic acid
  • Masoprocol
  • Masoprocolum
  • meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
  • meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
  • meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
  • meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
  • meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
  • meso-NDGA
  • meso-nordihydroguaiaretic acid
  • meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
  • Nordihydroguaiaretic acid
External IDs
  • CHX 100
  • CHX-100
  • INSM-18
  • INSM18
  • NSC-4291

Pharmacology

Indication

Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Masoprocol is a novel antineoplastic agent. It is not known exactly how masoprocol works. Laboratory experiments have shown that masoprocol prevents cells similar to the ones found in actinic keratoses from multiplying. Masoprocol was withdrawn from the U.S. market in June 1996.

Mechanism of action

Although the exact mechanism of action is not known, studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known.

TargetActionsOrganism
AArachidonate 5-lipoxygenase
inhibitor
Humans
USex hormone-binding globulinNot AvailableHumans
ATransient receptor potential cation channel subfamily M member 7
inhibitor
Humans
Absorption

Less than 1%-2% is absorbed through the skin over a 4-day period following application.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbroxolThe risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Bupivacaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Actinex

Categories

ATC Codes
L01XX10 — Masoprocol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dibenzylbutane lignans. These are lignan compounds containing a 2,3-dibenzylbutane moiety.
Kingdom
Organic compounds
Super Class
Lignans, neolignans and related compounds
Class
Dibenzylbutane lignans
Sub Class
Not Available
Direct Parent
Dibenzylbutane lignans
Alternative Parents
Phenylpropanes / Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzenoid / Catechol / Dibenzylbutane lignan skeleton / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
nordihydroguaiaretic acid (CHEBI:73468) / Lignans (C10719)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
7BO8G1BYQU
CAS number
27686-84-6
InChI Key
HCZKYJDFEPMADG-TXEJJXNPSA-N
InChI
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
IUPAC Name
4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
SMILES
C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1

References

General References
Not Available
Human Metabolome Database
HMDB0014325
KEGG Drug
D04862
KEGG Compound
C10719
PubChem Compound
71398
PubChem Substance
46508042
ChemSpider
64490
BindingDB
22372
RxNav
227239
ChEBI
73468
ChEMBL
CHEMBL313972
ZINC
ZINC000000012342
Therapeutic Targets Database
DNC001037
PharmGKB
PA164746493
Guide to Pharmacology
GtP Drug Page
Wikipedia
Masoprocol
MSDS
Download (69 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Pharmacoeconomics

Manufacturers
  • Univ arizona cancer center
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)185.5 °CPhysProp
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP3.44ALOGPS
logP4.76Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)9.21Chemaxon
pKa (Strongest Basic)-6.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area80.92 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity86.62 m3·mol-1Chemaxon
Polarizability33.63 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier-0.5361
Caco-2 permeable+0.6215
P-glycoprotein substrateSubstrate0.6654
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9144
Renal organic cation transporterNon-inhibitor0.886
CYP450 2C9 substrateNon-substrate0.7194
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.5171
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8891
CYP450 2D6 inhibitorInhibitor0.8262
CYP450 2C19 inhibitorInhibitor0.8628
CYP450 3A4 inhibitorNon-inhibitor0.5833
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5322
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8614
BiodegradationNot ready biodegradable0.9632
Rat acute toxicity2.1491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.6288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0fk9-0900000000-c156a7beced7bc5559ce
Mass Spectrum (Electron Ionization)MSsplash10-00di-0901000000-c0d0caa2c363f17f6c94
LC-MS/MS Spectrum - LC-ESI-qTOF , PositiveLC-MS/MSsplash10-0uyi-0960000000-911fb528895df2fd3880
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0911000000-ad449f20d75c55f665cc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0009000000-e4ec285fa36dfc6a32cc
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0umu-1913000000-10ae6930cc2d7c5da537
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0569000000-0be76b262d16bd10f5f8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01di-1960000000-cf5c7def081ffe43a3a6
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dr-0940000000-a6e397bb07ebabce6870
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0930000000-59f75118fd5dcd12eefb
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-188.7809239
predicted
DarkChem Lite v0.1.0
[M-H]-190.7654239
predicted
DarkChem Lite v0.1.0
[M-H]-191.9596239
predicted
DarkChem Lite v0.1.0
[M-H]-176.88368
predicted
DeepCCS 1.0 (2019)
[M+H]+188.6197239
predicted
DarkChem Lite v0.1.0
[M+H]+192.3554239
predicted
DarkChem Lite v0.1.0
[M+H]+192.1436239
predicted
DarkChem Lite v0.1.0
[M+H]+179.24168
predicted
DeepCCS 1.0 (2019)
[M+Na]+188.1116239
predicted
DarkChem Lite v0.1.0
[M+Na]+190.5514239
predicted
DarkChem Lite v0.1.0
[M+Na]+191.9265239
predicted
DarkChem Lite v0.1.0
[M+Na]+186.00096
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Audouin C, Mestdagh N, Lassoie MA, Houssin R, Henichart JP: N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase. Bioorg Med Chem Lett. 2001 Mar 26;11(6):845-8. [Article]
  2. Lambert JD, Meyers RO, Timmermann BN, Dorr RT: Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):85-90. [Article]
  3. Azadzoi KM, Heim VK, Tarcan T, Siroky MB: Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn. 2004;23(3):258-64. [Article]
  4. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, Hensley K: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004 Oct;91(1):133-43. [Article]
  5. Jeon SB, Ji KA, You HJ, Kim JH, Jou I, Joe EH: Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun. 2005 Mar 11;328(2):595-600. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  7. Chen HC, Xie J, Zhang Z, Su LT, Yue L, Runnels LW: Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase. PLoS One. 2010 Jun 17;5(6):e11161. doi: 10.1371/journal.pone.0011161. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxi...
Gene Name
TRPM7
Uniprot ID
Q96QT4
Uniprot Name
Transient receptor potential cation channel subfamily M member 7
Molecular Weight
212695.37 Da
References
  1. Chen HC, Xie J, Zhang Z, Su LT, Yue L, Runnels LW: Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase. PLoS One. 2010 Jun 17;5(6):e11161. doi: 10.1371/journal.pone.0011161. [Article]

Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:42